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Background: RNA binding motif 5 (RBM5) is a tumor suppressor gene that modulates apoptosis through the
regulation of alternative splicing of apoptosis-related genes. This study aimed to detect RBM5 expression in non-
small cell lung cancer (NSCLC) and to associate RBM5 expression with clinicopathological data from NSCLC patients
and EGFR and KRAS expression to better understand the potential role of RBM5 in NSCLC.
Method: Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting were
performed to detect expression of mRNA and protein, respectively, of RBM5, EGFR and KRAS in 120 paired non-
tumor and tumor samples of NSCLC.
Results: The data showed that expression of RBM5 mRNA and protein was significantly reduced in NSCLC
compared to normal tissues, whereas expression of both EGFR and KRAS genes was increased in NSCLC compared
to normal tissues. Furthermore, the reduced RBM5 protein expression correlated with smoking status, tumor stage
and lymph node metastasis of NSCLC, while overexpression of EGFR and KRAS proteins correlated with tumor stage
and lymph node metastasis of NSCLC. Overexpression of KRAS protein was more frequent in smokers with NSCLC.
In addition, expression of RBM5 mRNA and protein was negatively correlated with expression of EGFR and KRAS
mRNA and protein in NSCLC tissues.
Conclusion: This study suggests further evaluation of RBM5 expression is warranted for use of RBM5 as a biomarker
for NSCLC patients.
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Lung cancer is a significant worldwide health problem,
accounting for more than 1.5 million new cases and 1.3
million cancer-related deaths annually [1,2]. The 5-year
survival rate of lung cancer still remains at 13 to 15 %
for the past 3 decades, despite recent advances in lung
cancer early diagnosis, surgical techniques, and the de-
velopment of novel chemotherapeutic agents [3]. The
single most important risk factor for lung cancer is
tobacco smoke, responsible for 85 % of lung cancer inci-
dence. However, lung cancer incidence in developed* Correspondence: wke@jlu.edu.cn
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reproduction in any medium, provided the orcountries, like several European countries and the USA,
was noticeably reduced since 2000, mostly due to
tobacco cessation campaigning, whereas the incidence
rate in Asian countries, including China and Japan was
still shown to be increased [4]. Histologically, lung can-
cer can be divided into small cell lung cancer and non-
small cell lung cancer (NSCLC), which have totally dif-
ferent etiology and treatment options. NSCLC mainly
includes squamous cell carcinoma, adenocarcinoma, and
large cell carcinoma [5]. Molecularly, NSCLC develop-
ment is believed to be initiated by the activation of onco-
genes or inactivation of tumor suppressor genes [6].
Previous studies demonstrated that mutations in the
KRAS proto-oncogene are responsible for 10–30 % of
lung adenocarcinomas, while mutations and amplification
of EGFR are common in NSCLC and provide the basis ford. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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remains to be defined how tobacco smoke and other risk
factors cause the development of NSCLC, thus, further
study of the underlying mechanisms responsible for
NSCLC development and progression is truly needed to
provide novel strategies in early detection and effective
control of this deadly disease.
EGFR, also called HER-1/ErbB1, is a receptor tyrosine
kinase (TK) of the ErbB gene family, which contains four
closely related proteins, i.e., HER-1/ErbB1, HER-2/neu/
ErbB2, HER-3/ErbB3, and HER-4/ErbB4. The EGFR gene
is located at chromosome 7p12 and encodes a 170 kDa
membrane glycoprotein. Upon binding of specific
ligands, such as epidermal growth factor and transform-
ing growth factor-α, the receptor forms homodimers,
leading to receptor autophosphorylation and activation
of the signal cascade. This results in changes in expres-
sion of different genes that are crucial to tumor progres-
sion, including tumor growth, resistance to apoptosis,
invasion, and angiogenesis [8]. TK activity of EGFR is
frequently observed in NSCLC, which maybe dysregu-
lated by several oncogenic mechanisms, including EGFR
gene mutation, increased gene copy number, and EGFR
protein overexpression [9], as in HER-2, although to a
significantly lesser extent [10]. Therefore, targeting of
EGFR has achieved significant effects in the clinic; how-
ever, elevated EGFR activity is more frequent in never-
smokers than smokers, so is less effective in smoking-
related lung cancers [11]. In addition, the side effects
associated with EGFR targeting necessitate continued re-
search for more specific molecular targets.
KRAS, also known as GTPase KRAS, belongs to the
RAS gene family which encodes for a small protein with
a molecular weight of 21 kDa with guanosine tripho-
sphatase (GTPase) activity. KRAS acts as a molecular
on/off switch. Once it is turned on it recruits and acti-
vates proteins necessary for the propagation of growth
factors and other receptors' signals, such as c-Raf and PI
3-kinase, involved in many signal transduction pathways
[12,13]. The protein product of the normal KRAS gene
performs an essential function in normal tissue signaling,
and the mutation of a KRAS gene is an essential step in
the development of many cancers. Other members of the
RAS family include HRAS and NRAS. These proteins all
are regulated in the same manner and appear to differ
largely by their sites of action within the cell. Previous
studies have demonstrated that expression of KRAS was
increased in NSCLC, mutations of which were tobacco
smoke-related [14]. Although some studies showed that
KRAS and EGFR mutations are mutually exclusive and
exhibit contrasting characteristics such as clinical back-
ground, pathological features of patients, etc., the actual
correlation between these two genes and the effective ther-
apeutics for KRAS mutation in NSCLC are still unclear.RBM5 is one of the approximately 35 genes located in
the 370-kilobase tumor suppressor locus on chromosome
3p21.3, loss of which is the most frequent and earliest
event in NSCLC [15]. RBM5 plays an important role in
the induction of cell cycle arrest and apoptosis through
pre-mRNA splicing of multiple target genes, and inhibits
tumor transformation and the progression of several ma-
lignancies, including NSCLC [16–18]. However, there are
only a few studies to date on RBM5 expression in NSCLC.
Our previous study showed that HER2 overexpression
was able to downregulate expression of the RBM5 splices
variant RBM5+5+6 in breast cancer cells [19], moreover,
RBM5 is downregulated by the constitutively activated
RAS mutant protein, RAS(G12V), in rat embryonic fibro-
blast cells [20], which indicates a correlation between the
EGFR and RAS pathways and RBM5 expression. In light
of these findings, in this study we set out to examine the
expression of RBM5 in NSCLC tissue specimens and the
association of RBM5 expression with clinicopathological
data and the expression of KRAS and EGFR. This study
aims to explore the potential utility of RBM5 as a tumor
diagnosis marker in NSCLC.
Materials and Methods
Study population
In this study, we collected 120 cases of surgically
resected NSCLC and adjacent normal tissues from the
Jilin University Affiliated Hospitals between 2008 and
2010. After surgical removal, all of the samples were im-
mediately snap-frozen in liquid nitrogen and stored at
−80°C until total RNA was extracted by guanidinium/
cesium chloride ultracentrifugation. Patients’ data, in-
cluding sex, age at diagnosis, tumor histology, clinical
stage, and smoking history, were also collected from their
medical records. Clinical staging of lung cancers was per-
formed using the revised International System for Staging
Lung Cancer [21]. All samples were procured with informed
consent after each patient signed the consent form. This
study was approved by the Medical Ethics Committee of
the First and Second Affiliated Hospital of Jilin University,
Changchun, Jilin, China. The detailed outline of the charac-
teristics of our patient cohort is shown in Table 1.
Reverse transcription-polymerase chain reaction (RT-PCR)
The expression levels of RBM5, KRAS and EGFR mRNA
were determined using a semi-quantitative RT-PCR tech-
nique. Briefly, total RNA was isolated from lung tissues
using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer's instructions. Reverse tran-
scription was performed with 3 μg of total RNA in a final
volume of 10 μl, containing 10 mM dNTP, 0.5 μg oligo dT,
20 U RNasin and 200 U M-MLV reverse transcriptase
(Promega Corp., Madison, WI, USA). PCR was performed
in a final volume of 25 μl, containing 25 mM MgCl2,





Low(N) % P High(N) % P High(N) % P
Characteristic
Gender n
Male 73(61) 56 76.7 0.46 23 31.5 0.597 34 46.6 0.666
Female 47(39) 28 66.7 18 38.3 20 42.6
Age (years)
Less than 60 37(31) 26 70.3 0.996 12 32.4 0.586 16 43.2 0.796
Greaterthanorequalto60 83(69) 58 69.7 29 34.9 38 45.8
Smoking status
Former or Current 84(70) 66 78.6 0.001** 14 38.9 0.475 45 53.6 0.002**
Never 36(30) 18 50 27 32.1 8 22.2
Histology, n
Adenocarcinoma 47(39) 36 76.6 0.206 19 40.4 0.246 17 36.2 0.119
Squamous cell 73(61) 48 65.8 22 30.1 37 50.7
Lymph node Metastasis
Positive 60(50 %) 50 83 0.008** 27 45 0.009** 34 56.7 0.01*
Negative 60(50 %) 34 56.7 14 23.3 20 33.3
Tumor TNM stage
IA 16(13 %) 9 56 0.029** 3 18.7 0.031 2 12.5 0.022*
IB 18(15 %) 11 61 5 27.7 5 27.8
IIA 28(23 %) 17 60.7 6 35.2 7 25
IIB 23(19 %) 17 73.9 10 43.5 10 43.5
IIIA 20(17 %) 17 85 9 45 11 55
IIIB 15(13 %) 13 86.6 8 53.3 9 60
(Low) reduced expression patients.(High) increased expression patients. Values represent asymptotic two-tailed significance with asterisks denoting *P< 0.05 and
**P< 0.01, from the Pearson’s Chi-squared test.
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gen). PCR amplification was set at an initial 95°C for
5 min and then 28 (GAPDH), 30 (EGFR and KRAS) and
35 (RBM5) cycles of 95°C for 30 s, 55°C for 30s, 72°C for
45 s, and a final extension at 72°C for 10 min. After that,
the PCR products were separated by 1 % agarose gel elec-
trophoresis and visualized under UV light after 0.5 % eth-
idium bromide staining. Gene primers were designed
using Primer 5 software (Premier Biosoft International,
Palo Alto, CA, USA) and synthesized by Sangong Co. Ltd.
(Shanghai, China). The primer sequences were: GAPDH,
5'-GGGTGATGCTGGTGCTGAGTATGT-3' and 5'-AAG
AATGGGAGTTGCTGTTGAAGTC-3'; RBM5, 5'-ACAC
GATG GATGGAAGCCA-3' and 5'-TCTGCTCTGCCT
CTGACTT-3'; KRAS, 5'-TCTTGCCTCCCTACCTTCCA
CAT-3' and 5'-CTGTCAGATTCTCTTGAGCCCTG-3';
EGFR, 5'-TGATAGACGCAGATAGTCGCC-3' and 5'-TC
AGGGCACGGTAGAAGTTG-3'.
Protein extraction and Western blotting
Total cellular protein from lung tissue specimens was
extracted according to a previous study [19]. Proteinsamples (50 μg) were then separated by SDS-PAGE and
transferred onto a PVDF membrane (Millipore, Bedford,
MA). The primary antibodies were rabbit anti-human
RBM5, EGFR and KRAS antibodies from Abcam (MA,
USA) and an anti-β-actin antibody from Santa Cruz Bio-
tech, Inc. (Santa Cruz, CA, USA). The secondary anti-
body was a goat anti-rabbit IgG-HRP from Abcam.
Western blotting was carried out as previously described
[22], and the protein bands were visualized by Super-
Signal West Pico Chemiluminescent Substrate (Pierce,
Rockford, IL, USA), and the membranes were subjected
to X-ray autoradiography. Band intensities were deter-
mined with Quantity One software (Bio-Rad, Hercules,
CA, USA). Furthermore, we confirmed the reproducibil-
ity of the experiments at least three times. The results
were expressed as mean ± S.E.
Statistical analysis
Pearson’s Chi-squared test was performed to determine
the association of clinicopathological data with the expres-
sion of RBM5, EGFR, and KRAS mRNA and proteins in
NSCLC tissues, and the paired-samples Wilcoxon signed
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EGFR, KRAS mRNA and proteins between NSCLC and
adjacent normal tissues. Associations between RBM5,
EGFR, and KRAS were tested by using the spearman’s rho
test. All statistical analyses were performed using SPSS
software, version 17.0. (SPSS, Chicago, IL, USA). A p value
equal or less than 0.05 was considered statistically signifi-
cant. A 2-fold difference between control and test was
considered the cut-off point to define over- or under-
expression.
Results
Differential expression of RBM5 mRNA and protein in
NSCLC
In this study, we first detected the expression of RBM5
mRNA and protein in 120 paired NSCLC and adjacent
normal tissue specimens. Representative data are shown
in Figure 1A and Figure 2A. By comparison of normal
and tumor expression of RBM5 mRNA and protein at a
ratio of 2.0 as a cutoff point we found that expression of
RBM5 mRNA and protein was significantly reduced in
NSCLC vs. the non-tumor tissues (P = 0.037 and P= 0.03,
respectively). Specifically, 78 (65 %) had decreased ex-
pression of RBM5 mRNA and 84 (70 %) NSCLC tissues
had decreased expression of RBM5 protein. We next
examined the association of RBM5 protein expression
with the clinicopathological data for the NSCLC patients
and found that the decreased expression of RBM5 pro-
tein was significantly more frequent in smokers than
in non-smokers (66 vs. 18 cases or 78.6 % vs. 50 %;
P = 0.001). Reduced RBM5 protein expression in the
NSCLC tissues was also significantly positively correlated
with lymph node metastasis of NSCLC patients (50 vs.
34 or 83 % vs. 56.7 %; P = 0.008). RBM5 protein expres-
sion also associated with tumor stages. Decreased RBM5
protein expression was more frequently observed in
NSCLC patients with IIIA and III B stages compared to
those with I and IIA stages (Table 1).
Differential expression of EGFR mRNA and protein in
NSCLC
Next, we analyzed the expression of EGFR mRNA and
protein in 120 cases of NSCLC and adjacent normal tis-
sue specimens. The data are summarized in Figure 1A
and Figure 2A. By comparison of normal and tumor
expression of EGFR mRNA and protein at a ratio of 2.0
as a cutoff point, we found that expression of EGFR
mRNA and protein was significantly increased in NSCLC
tissues compared the non-tumor tissues (P = 0.024 and
P = 0.008, respectively). Specifically, increased expression
of EGFR mRNA was found in 45 (37.5 %) tumor tissues,
while the increased expression of EGFR protein was
found in 41 (34.2 %) tumor tissues. In lung adenocarcin-
oma, the increased expression of EGFR protein wasfound in 19 (40.4 %) tumor cases and, in squamous cell
carcinoma, 22 (30.1 %) cases had overexpressed EGFR
protein (P = 0.246). Furthermore, we found that the
increased expression of EGFR protein was more frequent
in lymph node metastasis of NSCLC compared to non-
metastatic NSCLCs (27 vs. 14 or 45 % vs. 23.3 %;
P = 0.009). Expression of EGFR protein also associated
with tumor stages. Increase EGFR protein expression
was more frequently observed in patients with IIIA and
IIIB compared to those in I and IIA. But there was no
association of EGFR expression with other clinicopatho-
logical data from NSCLC patients (Table 1).
Differential expression of KRAS mRNA and protein in
NSCLC
Expression of KRAS mRNA and protein in 120 cases of
NSCLC and adjacent normal tissue specimens is sum-
marized in Figure 1A and Figure 2A. By comparison of
normal and tumor expression of KRAS mRNA and pro-
tein at a ratio of 2.0 as a cutoff point, we found that ex-
pression of KRAS mRNA and protein was significantly
increased in NSCLC compared the non-tumor tissues
(P= 0.03 and P= 0.018, respectively). Specifically, increased
expression of KRAS mRNA was found in 52 (43 %) tumor
tissues, while the increased expression of KRAS protein
was found in 54 (45 %) tumor tissues. Moreover, the
increased expression of KRAS protein was found in 17
(36.2 %) adenocarcinoma samples and in 37 (50.7 %) squa-
mous cell carcinoma samples. Increased expression of
KRAS protein was more frequent in squamous cell carcin-
omas and in lymph node metastasis compared to non-
metastatic tumors (34 vs. 20 or 56.7 % vs. 33.3 %; P= 0.01).
Expression of KRAS protein was associated with tumor
stages and also occurred more frequently in ever-smokers
(P= 0.002; Table 1).
RBM5, EGFR and KRAS expression correlations in NSCLC
We examined the relationship between expression of
RBM5, EGFR, and KRAS in NSCLC and found that ex-
pression of RBM5 mRNA and protein was significantly
negatively correlated with expression of EGFR and KRAS
mRNA and protein in NSCLC tissues (p< 0.01; Tables 2
and 3).
Discussion
In this study, we analyzed the expression of RBM5,
EGFR, and KRAS genes in NSCLC and adjacent normal
tissue specimens and found that RBM5 expression was
reduced in NSCLC compared to the normal tissues,
whereas expression of both EGFR and KRAS genes was
increased in NSCLC compared to the normal tissues.
The reduced expression of RBM5 protein was associated
with tobacco smoke, tumor stages, and lymph node me-
tastasis of NSCLC, while overexpression of EGFR and
Figure 1 Expression of RBM5, EGFR and KRAS mRNA in NSCLC. A, Agarose gel of semi-quantitative RT-PCR data of RBM5, EGFR, and KRAS
mRNA expression in representative NSCLC and non-tumor specimens. Total RNA was isolated and subjected to semi-quantitative RT-PCR and
quantified using Quantity One software. B, Quantitative data from A. *p< 0.05 compared to the normal tissues using Wilcoxon signed rank test.
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Figure 2 Expression of RBM5, EGFR and KRAS protein in NSCLC. A, Western blot of RBM5, EGFR and KRAS protein expression in
representative tissue samples from NSCLC and non-tumor specimens. Total cellular protein was extracted, subjected to Western blot analysis and
quantified using Quantity One software. B, Quantitative data from A. *p< 0.05 compared to the normal tissues using Wilcoxon signed rank test.
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Correlation coefficient −0.961 −0.809
Sig.(2-tailed)A 0.000** 0.000**
N 120 120
aP-values represent asymptotic two-tailed significance with asterisks denoting
**P< 0.01, from the Spearman`s rho test.
Liang et al. Journal of Experimental & Clinical Cancer Research 2012, 31:36 Page 7 of 9
http://www.jeccr.com/content/31/1/36KRAS proteins was associated with tumor stages and
lymph node metastasis of NSCLC. Overexpression of
KRAS protein occurred more frequently in smokers with
NSCLC. Moreover, expression of RBM5 mRNA and pro-
tein was negatively associated with expression of EGFR
and KRAS mRNA and protein in NSCLC tissues. The
data from the current study suggest that expression of
RBM5 mRNA and protein is worth further evaluation as
a biomarker for tumor diagnosis.
Previous studies have shown that RBM5 expression
was frequently reduced in different cancers, including
breast cancer [20], human schwannoma [23] and 75 % of
primary lung cancer specimens [24]. In the present
study, expression levels of RBM5 protein were reduced
in NSCLC compared with the non-tumor tissues, sug-
gesting that RBM5 could play a role in suppression of
NSCLC development or progression. Furthermore, the
expression level of RBM5 was shown to be high in the
adult thymus and low in the fetal thymus, indicating that
RBM5 expression may be developmentally regulated
[17]. RBM5 protein is a negative regulator of cell prolif-
eration: overexpression of the full length LUCA-15/
RBM5 in breast cancer CEM-C7 and NSCLC A549 cells
suppressed cell proliferation through induction of apop-
tosis and arrest of tumor cells at the G1 phase of the cell
cycle [16]. These data together suggest that the loss of
RBM5 expression in different cancer tissues and cells
contributes to tumor growth via regulation of cell prolif-
eration and apoptosis.
Moreover, our current study also showed that expres-
sion of RBM5 protein in NSCLC tissues was negatively
correlated with tobacco smoke, The data that decreased
expression of RBM5 protein was more frequent in smo-




Correlation coefficient −0.943 −0.842
Sig. (2-tailed)A 0.000** 0.000**
N 120 120
aP-values represent asymptotic two-tailed significance with asterisks denoting
**P< 0.01, from the Spearman`s rho test.may lead to the loss of RBM5 expression in NSCLC, which
is in agreement with previous studies that had shown
deletions at 3p21.3 were the earliest lesions in lung cancer,
and were associated with smoking alone [15].
In addition, tumor metastasis, the major cause of cancer
death, is a multistep process that requires interactions
between cancer cells, stromal cells, and the extracellular
matrix. In this study, we found that reduced expression of
RBM5 protein was associated with lymph node metastasis
of NSCLC, indicating that RBM5 may play a potential role
in the suppression of tumor metastasis. It is further corro-
borated by other studies, including (1) RBM5 downregula-
tion as a part of a molecular signature of 17 genes for
detection of metastasis of multiple solid tumor types
[25,26]: solid tumors with these gene signatures had high
metastasis rates and poor clinical outcomes, and (2) dem-
onstration that RBM5 may regulate inhibition of metasta-
sis in lung cancer through the upregulation of some
metastasis-related genes including Rac1, B-catenin, colla-
gen and laminin [27]. Taken together, in the light of all the
observations, we suggest that RBM5 could be a promising
candidate towards lung cancer clinical management in
terms of the metastatic status. Nevertheless, the detailed
molecular mechanism involved in RBM5-mediated metas-
tasis needs to be further investigated.
Our data also showed an inverse correlation between
RBM5 expression and EGFR and KRAS expression in
NSCLC. Alteration of EGFR expression and gene ampli-
fication has been reported as between 7 % and 45 % in
lung cancer cases [28–30], which may also be due to var-
iations in techniques, criteria to determine positivity, and
inter-observer variability [29,30]. In our study, overex-
pression of EGFR was found in 33 % of specimens of
NSCLC, with a somewhat higher incidence in ACs than
in SCCs. Moreover, overexpression of KRAS was found
in 45 % of specimens of NSCLC, with a somewhat higher
incidence in SCCs than in ACs. Overexpression of EGFR
and KRAS proteins was associated with lymph node me-
tastasis and with a more advanced pathologic stage. Our
current study for the first time demonstrated a correl-
ation between the expression levels of RBM5, EGFR and
KRAS in NSCLC tissues, with the data suggesting that
disruption of RBM5 apoptosis-induced activity and tumor
suppressor function is consistent with the potent oncogenic
activity associated with EGFR and KRAS overexpression.
The differential expression of these three genes in NSCLC
suggests the presence of a complex regulatory network
involving tumor suppression and oncogenic expression.
Details of the inverse relationship between RBM5,
EGFR and KRAS are only beginning to be delineated
[19,31]. For instance, HER2 overexpression was shown
to affect the alternative splicing of RBM5. One cytotoxic
isoform, RBM5+ 5+ 6 t, was downregulated in breast
cancer cells (both primary tumors and a cell line) that
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tors in the EGFR pathway may function as upstream
modulators of RBM5 function and/or expression. In
order to investigate this hypothesis, we downregulated
EGFR in NCI-H1975 lung adenocarcinoma cells that
have activated EGFR, using small interfering RNA, and
analyzed RBM5 expression [CMJ, submitted]. The results
of this study demonstrated that downregulation of acti-
vated EGFR, in the NCI-H1975 lung cancer cell line, did
not, in fact, correlate with upregulation of RBM5, sug-
gesting that RBM5 functions upstream of EGFR. That
deletion of the region encompassing the RBM5 gene is
one of the earliest lesions associated with smoking does
suggest that downregulation of RBM5 is necessary for
cancer initiation events. In addition, we recently
observed that overexpression of RBM5 induced expres-
sion of KRAS in the A549 lung cancer cell line and
decreased expression of KRAS in the MCF-7 breast can-
cer cell line [Wang et al, unpublished data], suggesting
that RBM5 functions upstream of KRAS, albeit with dif-
ferent outcomes, depending on tissue of origin.
In conclusion, our study suggests that further study
of RBM5, EGFR and KRAS gene function and inter-
relationships will provide a better understanding of the
role these genes play in NSCLC development and
progression.
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